Loading clinical trials...

COMPLETEDNA

Secondary Prophylaxis Gastric Variceal Bleed

Endoscopic Cyanoacrylate Injection Versus Beta-Blockers for Secondary Prophylaxis of Gastric Variceal Bleed

NCT00888784•Govind Ballabh Pant Hospital

Summary

The investigators conducted a randomized, controlled trial (RCT) to study the efficacy of beta blockers versus endoscopic cyanoacrylate injection in the prevention of gastric variceal (GOV2 or IGV1) rebleeding and improvement in survival.

Eligibility

Age

10 - 70 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients with GOV2 without esophageal varix or IGV1, who had bled from GV were included

Exclusion Criteria

•Presence of esophageal varix
•GOV2 with GOV1; contraindications to beta-blocker therapy and cyanoacrylate injection
•Prior injection of cyanoacrylate or sclerotherapy for GV or GV ligation, transjugular intrahepatic portosystemic shunt, balloon-occluded retrograde transvenous obliteration, balloon-occluded endoscopic injection sclerotherapy of GV, shunt operation for prevention of rebleeding from GV
•Patients already on beta-blocker or nitrates
•Undetermined origin of bleeding from esophageal varix or gastric varix
•Hepatic encephalopathy grade III/IV
•Hepatorenal syndrome
•Hepatocellular carcinoma
•Presence of deep jaundice (serum bilirubin \> 10 mg/dl)
•Uremia
+3 more criteria

Locations (1)

G B Pant Hospital

New Delhi, National Capital Territory of Delhi, India

Key Dates

Start Date

August 1, 2006

Primary Completion Date

January 1, 2009

Completion Date

January 1, 2009

Last Updated

April 28, 2009

Enrollment

ACTUAL participants

Conditions

Cirrhosis

Interventions

Endoscopic Cyanoacrylate injection

PROCEDURE

beta-blocker (propranolol)

DRUG

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

NCT05597488

Cirrhosis Portal

View study

RECRUITINGNA

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

NCT06932783

Cirrhosis

View study

RECRUITING

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 28, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Secondary Prophylaxis Gastric Variceal Bleed

Inclusion Criteria

Exclusion Criteria

EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

Remote Electrical Stimulation for Pain and Depression Treatment in Cirrhosis

Prevalence of Gastric Motor Dysfunction and Upper GI Symptoms in Gastric Antral Vascular Ectasias

Mechanism of TIPS to Improve Sarcopenia

Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care

Verification of Risk Factors of Thrombohemorrhagic Complications in Recipients After Related Liver Transplantation